Shanna Bernstein
National Institutes of Health
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Shanna Bernstein.
The Journal of Clinical Endocrinology and Metabolism | 2015
Britni R. Belcher; David Berrigan; Alexia Papachristopoulou; Sheila M. Brady; Shanna Bernstein; Robert J. Brychta; Jacob D. Hattenbach; Ira L. Tigner; Amber B. Courville; Bart Drinkard; Kevin P. Smith; Douglas R. Rosing; Pamela L. Wolters; Kong Y. Chen; Jack A. Yanovski
CONTEXT Limited data suggest that interrupting sedentary behaviors with activity improves metabolic parameters in adults. OBJECTIVE We tested whether interrupting sitting with short, moderate-intensity walking bouts improved glucose tolerance in children. DESIGN Participants underwent two experimental conditions in random order on different days: continuous sitting for 3 hours or sitting interrupted by walking (3 min of moderate-intensity walking every 30 min). Insulin, C-peptide, glucose, and free fatty acids were measured every 30 minutes for 3 hours during an oral glucose tolerance test. Area under the curve (AUC) was calculated from hormone and substrate measurements. Children were given a buffet meal after each condition. SETTING The study was conducted at the National Institutes of Health Hatfield Clinical Research Center. PARTICIPANTS Twenty-eight normal-weight 7-11 year olds participated. MAIN OUTCOMES Patterns of substrate/hormone secretion and AUC, as well as energy intake, were examined by experimental condition. RESULTS Interrupting sitting resulted in a 32% lower insulin AUC (P < .001), 17% lower C-peptide AUC (P < .001), and 7% lower glucose AUC (P = .018) vs continuous sitting. Mixed model results indicated that insulin (P = .036) and free fatty acid concentrations (P = .009) were significantly lower in the interrupted vs the continuous sitting condition. Lunchtime buffet meal energy intake did not significantly differ between the conditions (975 ± 387 vs 963 ± 309 kcal; P = .85). CONCLUSIONS Interrupting sedentary time with brief moderate-intensity walking improved short-term metabolic function in non-overweight children without increasing subsequent energy intake. These findings suggest that interrupting sedentary behavior may be a promising prevention strategy for reducing cardiometabolic risk in children.
Obesity | 2015
Nichole R. Kelly; Lauren B. Shomaker; Courtney K. Pickworth; Sheila M. Brady; Amber B. Courville; Shanna Bernstein; Natasha A. Schvey; Andrew P. Demidowich; Ovidiu Galescu; Susan Z. Yanovski; Marian Tanofsky-Kraff; Jack A. Yanovski
Eating in the absence of hunger (EAH) refers to the consumption of palatable foods in a sated state. It has been proposed that EAH promotes excess weight gain in youth; yet there are limited prospective data to support this hypothesis. We examined whether EAH at baseline predicted increases in body mass (BMI and BMIz) and fat mass (kg) 1 year later among adolescent boys and girls.
JCI insight | 2018
Jenny E. Blau; Viviana Bauman; Ellen M. Conway; Paolo Piaggi; Mary Walter; Elizabeth C. Wright; Shanna Bernstein; Amber B. Courville; Michael T. Collins; Kristina I. Rother; Simeon I. Taylor
BACKGROUND Sodium glucose cotransporter-2 (SGLT2) inhibitors are the most recently approved class of drugs for type 2 diabetes and provide both glycemic efficacy and cardiovascular risk reduction. A number of safety issues have been identified, including treatment-emergent bone fractures. To understand the overall clinical profile, these safety issues must be balanced against an attractive efficacy profile. Our study was designed to investigate pathophysiological mechanisms mediating treatment-emergent adverse effects on bone health. METHODS We conducted a single-blind randomized crossover study in hospitalized healthy adults (n = 25) receiving either canagliflozin (300 mg/d) or placebo for 5 days. The primary end-point was the drug-induced change in AUC for plasma intact fibroblast growth factor 23 (FGF23) immunoactivity between 24 and 72 hours. RESULTS Canagliflozin administration increased placebo-subtracted mean levels of serum phosphorus (+16%), plasma FGF23 (+20%), and plasma parathyroid hormone (PTH) (+25%), while decreasing the level of 1,25-dihydroxyvitamin D (-10%). There was substantial interindividual variation in the magnitude of each of these pharmacodynamic responses. The increase in plasma FGF23 was correlated with the increase in serum phosphorus, and the decrease in plasma 1,25-dihydroxyvitamin D was correlated with the increase in plasma FGF23. CONCLUSIONS Canagliflozin induced a prompt increase in serum phosphorus, which triggers downstream changes in FGF23, 1,25-dihydroxyvitamin D, and PTH, with potential to exert adverse effects on bone health. These pharmacodynamic data provide a foundation for future research to elucidate pathophysiological mechanisms of adverse effects on bone health, with the objective of devising therapeutic strategies to mitigate the drug-associated fracture risk. TRIAL REGISTRATION ClinicalTrial.gov (NCT02404870). FUNDING Supported by the Intramural Program of NIDDK.
Journal of Clinical Investigation | 2018
Rebecca J. Brown; Areli Valencia; Megan Startzell; Elaine Cochran; Peter Walter; H. Martin Garraffo; Hongyi Cai; Ahmed M. Gharib; Ronald Ouwerkerk; Amber B. Courville; Shanna Bernstein; Robert J. Brychta; Kong Y. Chen; Mary Walter; Sungyoung Auh; Phillip Gorden
BACKGROUND. Recombinant leptin (metreleptin) ameliorates hyperphagia and metabolic abnormalities in leptin-deficient humans with lipodystrophy. We aimed to determine whether metreleptin improves glucose and lipid metabolism in humans when food intake is held constant. METHODS. Patients with lipodystrophy were hospitalized for 19 days, with food intake held constant by a controlled diet in an inpatient metabolic ward. In a nonrandomized, crossover design, patients previously treated with metreleptin (n = 8) were continued on metreleptin for 5 days and then taken off metreleptin for the next 14 days (withdrawal cohort). This order was reversed in metreleptin-naive patients (n = 14), who were reevaluated after 6 months of metreleptin treatment on an ad libitum diet (initiation cohort). Outcome measurements included insulin sensitivity by hyperinsulinemic-euglycemic clamp, fasting glucose and triglyceride levels, lipolysis measured using isotopic tracers, and liver fat by magnetic resonance spectroscopy. RESULTS. With food intake constant, peripheral insulin sensitivity decreased by 41% after stopping metreleptin for 14 days (withdrawal cohort) and increased by 32% after treatment with metreleptin for 14 days (initiation cohort). In the initiation cohort only, metreleptin decreased fasting glucose by 11% and triglycerides by 41% and increased hepatic insulin sensitivity. Liver fat decreased from 21.8% to 18.7%. In the initiation cohort, changes in lipolysis were not independent of food intake, but after 6 months of metreleptin treatment on an ad libitum diet, lipolysis decreased by 30% (palmitate turnover) to 35% (glycerol turnover). CONCLUSION. Using lipodystrophy as a human model of leptin deficiency and replacement, we show that metreleptin improves insulin sensitivity and decreases hepatic and circulating triglycerides and that these improvements are independent of its effects on food intake. TRIAL REGISTRATION. ClinicalTrials.gov NCT01778556 FUNDING. This research was supported by the intramural research program of the NIDDK.
Diabetes Care | 2018
Miranda M. Broadney; Britni R. Belcher; David Berrigan; Robert J. Brychta; Ira L. Tigner; Faizah Shareef; Alexia Papachristopoulou; Jacob D. Hattenbach; Elisabeth K. Davis; Sheila M. Brady; Shanna Bernstein; Amber B. Courville; Bart E. Drinkard; Kevin P. Smith; Douglas R. Rosing; Pamela L. Wolters; Kong Y. Chen; Jack A. Yanovski
OBJECTIVE Sedentary children have greater risk of developing abnormalities in glucose homeostasis. We investigated whether interrupting sedentary behavior (sitting) with very short periods of walking would improve glucose metabolism without affecting dietary intake in children with overweight or obesity. We hypothesized that interrupting sitting with short bouts of moderate-intensity walking would decrease insulin area under the curve (AUC) during an oral glucose tolerance test (OGTT) compared with uninterrupted sitting. RESEARCH DESIGN AND METHODS Overweight/obese (BMI ≥85th percentile) children 7–11 years of age underwent two experimental conditions in random order: prolonged sitting (3 h of continuous sitting) and interrupted sitting (3 min of moderate-intensity walking at 80% of ventilatory threshold every 30 min for 3 h). Insulin, C-peptide, and glucose were measured every 30 min for 3 h during an OGTT. Each session was followed by a buffet meal. Primary outcomes were differences in OGTT hormones and substrates and in buffet meal intake by condition. RESULTS Among 35 children with complete data, mixed-model results identified lower insulin and C-peptide in the interrupted condition (P = 0.007 and P = 0.029, respectively); the intervention reduced insulin AUC by 21% (P < 0.001) and C-peptide AUC 18% (P = 0.001) and improved estimated insulin sensitivity (P = 0.013). Neither buffet total energy intake (1,262 ± 480 vs. 1,260 ± 475 kcal; P = 0.89) nor macronutrient composition of the meal (P values >0.38) differed between conditions significantly. CONCLUSIONS Interrupting sitting with brief moderate-intensity walking improved glucose metabolism without significantly increasing energy intake in children with overweight or obesity. Interrupting sedentary behavior may be a promising intervention strategy for reducing metabolic risk in such children.
Nutrition | 2018
Suzanne Bowser; Nicole Farnsworth; Kate Russell; Haley Schlechter; Shanna Bernstein; Amber B. Courville; Kirsten Zambell; Monica C. Skarulis; Ranganath Muniyappa
OBJECTIVE Research suggests a difference in sweet taste perception between non-Hispanic black (NHB) and non-Hispanic white (NHW) adults; however, limited research has examined sweet taste perception in relation to the dietary intake of sweet products. The aim of this study was to examine sweet taste perception and the consumption of sweet foods, beverages, and sugar in NHB and NHW adults, and to evaluate whether sweet taste perception is associated with dietary intake. METHODS This cross-sectional study examined the association between race, sweet taste perception and sweet food, beverages, and sugar consumption in healthy, NHB and NHW adults. Seven day food records were analyzed in Nutrition Data System for Research software. Intensity of sweet taste perception was tested and the general labeled magnitude scale method was used to facilitate group comparisons. Independent t tests, Mann-Whitney tests, and Pearson correlations were used to assess associations. RESULTS Participants were NHB (n = 98) and NHW (n = 90) adults, 41 ± 1 y of age (mean ± SEM) with energy intake of 2271 ± 53 kcal. Body mass index was higher in NHBs than in NHWs (36 ± 1 versus 32 ± 1 kg/m2, P = 0.048), but no differences were observed in age, energy consumption, or total sugar intake. Sweet taste perception rating (median [interquartile range] NHB: 73.5 [63.9-83], NHW: 52.1 [46.4-57.7]; P = 0.001) and added sugar intake (NHB: 39.4 g/1000 kcal [36.3-42.4], NHW: 30 g/1000 kcal [26.7-33.4]; P < 0.001) were greater in NHB. Perceived sweet taste intensity was positively associated with consumption of servings of sweet products among NHBs (R2 = 0.057, P = 0.018) but not NHWs (R2 = -0.012, P = 0.314). CONCLUSIONS NHBs have a higher intensity of sweet taste perception than NHWs. The positive association of sweet taste perception and sweet product consumption in NHBs suggests that a higher intensity of sweet taste perception may be associated with an increased proportion of energy consumption from added sugars.
Fatigue: Biomedicine, Health & Behavior | 2018
Michele M. Tana; Hawwa Alao; Nevitt Morris; Shanna Bernstein; Jacob D. Hattenbach; Rahiya Binte Rehman; Robert J. Brychta; Souvik Sarkar; Xiongce Zhao; Mary Walter; Ashura Buckley; Kong Chen; Yaron Rotman
ABSTRACT Aims: We sought to examine whether disturbances in central and peripheral circadian rhythms were related to the experience of fatigue in patients with chronic liver disease (CLD).Methods: Fatigued and non-fatigued patients with compensated CLD were enrolled in a prospective pilot study. Patients underwent a one week evaluation of free-living sleep and physical activity patterns, followed by a 24-hour admission, during which they underwent serial blood sampling, polysomnography, a 6-minute walk test and continuous core temperature measurements under standardized conditions. Blood samples were analyzed for liver tests, melatonin levels, lipids, and cortisol. Circadian rhythms were analyzed using single cosinor analyses. Results: Six fatigued and six non-fatigued patients were studied; five participants had cirrhosis. Fatigue severity was positively associated higher peak melatonin levels (rho = 0.59, p = 0.04) and a delay in night-time melatonin peak and inversely associated with sleep efficiency (rho = −0.63, p = 0.04). Polysomnography, 6-minute walk test, and core temperature measurements did not differ significantly between the fatigued and non-fatigued patients. Although liver enzymes, bilirubin and albumin demonstrated a circadian pattern, it was not associated with fatigue. Fatigued patients showed a blunted and delayed cortisol rhythm and fatigue was strongly correlated with cortisol amplitude (rho = −0.77, p = 0.004) and phase (r = −0.66, p = 0.02). Conclusion: Subtle aberrations in melatonin and adrenal circadian rhythms, as well as reduced sleep efficiency, likely contribute to fatigue in patients with CLD. These abnormalities may ultimately be a therapeutic target to improve quality of life for fatigued patients with CLD.
Journal of the Academy of Nutrition and Dietetics | 2016
Shanna Bernstein; Kirsten Zambell; Marcelo Amar; Carolina Arango; Rachel C. Kelley; Susan G. Miszewski; Samantha Tryon; Amber B. Courville
Journal of the Academy of Nutrition and Dietetics | 2018
S. Andrus; N. Hayat; A. Kuemmerle; E. Leahy; Shanna Bernstein; K. Zambell; S. Chung; A. Sumner; Amber B. Courville
Diabetes | 2018
Amber B. Courville; Shanna Bernstein; Mirella Galvan-De La Cruz; Anthony Onuzuruike; Nirupa R. Matthan; Alice H. Lichtenstein; Anne E. Sumner; Stephanie T. Chung